600+ sources. One page. See who else covered it.
The transaction combines two companies marketing nearly a dozen neurological drugs that bring in steady, but not blockbuster sales for conditions such as opioid use disorder and Parkinson's.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
Shefali Agarwal works constantly. “I’m very passionate about what I do. I love getting good drugs to patients, so I work a lot,” Agarwal, the US-based CEO of Sironax, said in a December 2025 interview…
A basic bias in how the brain processes self-relevant information might contribute to severe body image preoccupations. New research shows that individuals with body dysmorphic traits learn and…
by Junjie Lin, Mika Kivimäki, Zifan Zhang, Hui Wang, Yangyang Cheng, Xiaolin Xu Background Impairments in physical, psychological, and cognitive functioning are associated with an increased risk of…
In a clinical trial of adults with HIV-related cryptococcal disease, those treated with a two-drug combination had a 21% lower risk of dying than those treated with just one drug.
While Black and Hispanic families are enthusiastic about research participation, other provider- and system-focused factors may influence their involvement in pediatric oncology clinical trials, a UT…
☢️ Curium spends $8B for Lantheus: Curium is buying fellow radiopharma company Lantheus for $102.5 per share. Lantheus shareholders may receive $12 more per share if certain targets are achieved ...